Novartis will officially spin its Alcon eye-care business off into a separately traded standalone business unit on April 9, 2019.
FCB Health Network chief commercial officer Michael Guarino announced the launch of Solve(d), a new offering that enhances the evidence-based planning and execution of clients’ healthcare marketing strategies and tactics.
Switzerland’s Novartis pledged to nearly triple its number of biosimilar drugs on the market by 2020, raising its bet that cheaper versions of blockbuster cancer and immune system medicines will snatch billions in rivals’ profits. Novartis’s Sandoz generics unit aims to be selling eight biosimilars, compared with three now, as patents on original drugs expire. […]
Much has been written about the impact of digital media on the life sciences industry. However, an area less discussed is how to maximize that impact globally, and in particular how to organize for success.